Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...
Condition: Sexual Assault Intervention: Behavioral: Motivate-The-Bystander (MTB) Sponsors: University of Nebraska Lincoln; University of Nebraska Recruiting
Condition: Chronic Kidney Diseases Intervention: Dietary Supplement: Cholecalciferol Sponsors: University of Nebraska; University of Nebraska, Omaha Not yet recruiting
Condition: Chronic Obstructive Pulmonary Disease Intervention: Other: walking on incline or walking at increasing speed Sponsors: VA Office of Research and Development; University of Nebraska, Omaha Not yet recruiting
Condition: Osteopenia Intervention: Device: Spry Belt Sponsors: Theranova, L.L.C.; National Institute on Aging (NIA); University of Nebraska Recruiting
Conditions: Fatigue; Self Efficacy; Quality of Life; Physical Activity; Lung Cancer; Non-Small Cell Lung Cancer Interventions: Behavioral: Light Physical Activity 1; Behavioral: Light Physical Activity 2; Behavioral: Support Education Activity Sponsors: University of Nebraska; Spectrum Health Hospitals; Ingham Regional Medical Center; Sparrow Clinical Research Institute; Munson Medical Center Recruiting
Conditions: Mild Cognitive Impairment; Memory Loss Intervention: Device: Transcranial magnetic stimulation Sponsors: University of Nebraska; National Institute of General Medical Sciences (NIGMS) Recruiting
Condition: Weight Loss Interventions: Behavioral: Mobile Technology Plus; Behavioral: Mobile Technology Sponsors: University of Nebraska; Northeast Nebraska Public Health Department Active, not recruiting
Condition: PreDiabetes Interventions: Behavioral: Online diabetes prevention program; Behavioral: Standard Care Sponsors: Omada Health, Inc.; University of Nebraska; Wake Forest University Health Sciences Active, not recruiting
Conditions: Smoking Cessation; Substance Use Disorder Interventions: Behavioral: Intensive Referral Intervention Group; Behavioral: Standard Practice Facilitated Group Sponsor: University of Nebraska Active, not recruiting
Condition: Diabetes Mellitus, Type 2 Intervention: Behavioral: Text messaging Sponsors: University of Nebraska Lincoln; The Methodist Hospital System Completed
Conditions: Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma; Untreated Chronic Lymphocytic Leukemia; Vitamin D Deficiency Interventions: Dietary Supplement: Cholecalciferol; Other: Laboratory Biomarker Analysis Sponsors: University of Nebraska; National Cancer Institute (NCI) Recruiting
Condition: Human Metapneumovirus and Human Parainfluenza Infection Interventions: Biological: mRNA-1653; Biological: Placebo Sponsor: ModernaTX, Inc. Recruiting
Condition: Cystic Fibrosis-related Diabetes Intervention: Diagnostic Test: Measurement of differentially methylated insulin DNA Sponsors: University of Nebraska; Cystic Fibrosis Foundation Recruiting
Conditions: Increasing Functional Communicative Behavior; Decreasing Destructive Behavior; Analysis of Treatment Dosage; Empirically Determined Reinforcement Schedule Thinning Interventions: Behavioral: Functional communication training; Behavioral: RaC-enhanced functional communication training Sponsors: University of Nebraska; Utah State University Recruiting
Conditions: Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer Interventions: Drug: gemcitabine hydrochloride; Drug: leucovorin calcium; Drug: fluorouracil; Drug: nelfinavir mesylate; Radiation: stereotactic body radiation therapy; Radiation: hypofractionated radiation therapy; Procedure: therapeutic conventional surgery Sponsors: University of Nebraska; National Cancer Institute (NCI) Completed
Condition: Cancer Interventions: Dietary Supplement: Vitamin D3; Dietary Supplement: Calcium carbonate Sponsors: Creighton University; National Institutes of Health (NIH); National Cancer Institute (NCI) Completed
Condition: Recurrent Small Cell Lung Carcinoma Interventions: Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Drug: Topotecan Hydrochloride Sponsors: University of Nebraska; National Cancer Institute (NCI) Completed
Condition: Lung Cancer Interventions: Other: questionnaire administration; Procedure: computed tomography; Procedure: evaluation of cancer risk factors; Procedure: study of high risk factors Sponsors: University of Nebraska; National Cancer Institute (NCI) Completed
Conditions: Obesity; Apathy Interventions: Behavioral: MOVE; Behavioral: medical crisis councelling; Drug: methyphenidate Sponsor: VA Nebraska Western Iowa Health Care System Completed
Conditions: HER2 Positive Breast Carcinoma; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7 Interventions: Drug: Cyclophosphamide; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Biological: Trastuzumab Sponsors: University of Nebraska; National Cancer Institute (NCI) Active, not recruiting
Conditions: Breast Cancer; Breast Carcinoma; Cancer of Breast; Malignant Tumor of Breast Interventions: Drug: Palbociclib; Drug: Letrozole; Drug: Fulvestrant; Procedure: Optional research biopsy; Drug: Goserelin; Procedure: Research blood draw; Procedure: Circulating tumor cell blood draw; Procedure: Tumor biopsy (optional) Sponsors: Washington University School of Medicine; Pfizer Recruiting
Conditions: Metabolic Syndrome; Dyslipidemias; Insulin Resistance; Hypertension Interventions: Other: No exercise intervention group; Behavioral: Resistance band exercise intervention group Sponsor: Pusan National University Completed
Condition: Lyme Borreliosis, Nervous System Interventions: Biological: VLA15 with Alum; Biological: VLA15 without Alum Sponsor: Valneva Austria GmbH Completed
Condition: Heart Failure Interventions: Device: Mobile phone app (VAD Care App); Other: Usual LVAD Care Sponsors: University of Michigan; Washington University School of Medicine; National Institute of Nursing Research (NINR) Completed
Conditions: Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Interventions: Other: Laboratory Biomarker Analysis; Drug: Venetoclax Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Recruiting
Conditions: Dyspnea; Non-small Cell Lung Cancer; Small Cell Lung Cancer Interventions: Drug: lisinopril; Drug: placebo Sponsors: Mayo Clinic; National Cancer Institute (NCI) Active, not recruiting
Conditions: Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Interventions: Other: Laboratory Biomarker Analysis; Drug: Ruxolitinib Phosphate Sponsors: University of Nebraska; National Cancer Institute (NCI) Active, not recruiting
Conditions: Heart Transplant Failure and Rejection; Heart Failure; Heart Diseases; Heart Failure,Congestive; Transplant; Failure, Heart; Transplant Failure Intervention: Sponsors: University of British Columbia; Canadian Institutes of Health Research (CIHR); PROOF Centre of Excellence; Duke University; University of Nebraska; Toronto General Hospital; St. Paul's Hospital, Canada Recruiting
Condition: Smith-Lemli-Opitz Syndrome Intervention: Drug: Cholic Acid Sponsors: University of Nebraska; University of Colorado, Denver; Children's Hospital Medical Center, Cincinnati; University of Pittsburgh Not yet recruiting
Condition: Head and Neck Cancer Interventions: Drug: BMX-001; Radiation: Radiation Therapy; Drug: Cisplatin Sponsors: BioMimetix JV, LLC; Duke University Recruiting
Condition: Respiratory Syncytial Virus Infections Interventions: Biological: RSV F vaccine with adjuvant; Biological: Formulation buffer Sponsors: Novavax; Bill and Melinda Gates Foundation Completed
Condition: Previously Treated Non-Small Cell Lung Cancer Intervention: Drug: Screening Platform Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29 Interventions: Other: Usual care disease monitoring; Other: Serum Tumor Marker directed disease monitoring; Other: Quality-of-Life Assessment; Other: Anxiety Questionnaire Administration Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma; Stage IV Uterine Corpus Cancer AJCC v7; Stage IVA Uterine Corpus Cancer AJCC v7; Stage IVB Uterine Corpus Cancer AJCC v7 Interventions: Drug: Cediranib; Drug: Cediranib Maleate; Drug: Olaparib Sponsors: National Cancer Institute (NCI); NRG Oncology Active, not recruiting
Conditions: Ductal Breast Carcinoma; Invasive Breast Carcinoma; Lobular Breast Carcinoma; Medullary Breast Carcinoma; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Tubular Breast Carcinoma Interventions: Radiation: Radiation Therapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment; Other: Laboratory Biomarker Analysis; Radiation: Hypofractionated Radiation Therapy Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Conditions: Cardiotoxicity; HER2/Neu Positive; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Carvedilol; Other: Laboratory Biomarker Analysis; Other: Patient Observation Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Extensive Stage Lung Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide; Biological: Nivolumab Sponsor: National Cancer Institute (NCI) Active, not recruiting
Condition: Node Positive HER2 Negative Breast Cancer Interventions: Other: Placebo; Drug: Aspirin Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group Recruiting
Conditions: Invasive Breast Carcinoma; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma Interventions: Other: Laboratory Biomarker Analysis; Other: Patient Observation; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsor: National Cancer Institute (NCI) Recruiting
Condition: Breast Carcinoma Interventions: Other: Health Education Program; Other: Weight Loss Intervention Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group Recruiting
Conditions: Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Drug: Crizotinib; Drug: Savolitinib; Drug: Sunitinib; Drug: Sunitinib Malate Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Conditions: Breast Carcinoma Metastatic in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma Interventions: Drug: Cisplatin; Other: Laboratory Biomarker Analysis; Other: Placebo; Drug: Veliparib Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Metastatic Cutaneous Melanoma; Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Cutaneous Melanoma; Recurrent Non-Cutaneous Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage III Mucosal Melanoma of the Head and Neck AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7; Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7; Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7 Interventions: Biological: Ipilimumab; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Biological: Recombinant Interferon Alfa-2b Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Tamoxifen Citrate; Drug: Z-Endoxifen Hydrochloride Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Recurrent Cervical Carcinoma; Stage IV Cervical Cancer AJCC v6 and v7; Stage IVA Cervical Cancer AJCC v6 and v7; Stage IVB Cervical Cancer AJCC v6 and v7 Interventions: Other: Laboratory Biomarker Analysis; Biological: Nivolumab Sponsors: National Cancer Institute (NCI); NRG Oncology Active, not recruiting
Condition: Colorectal Cancer Interventions: Biological: cetuximab; Drug: irinotecan hydrochloride; Drug: vemurafenib Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Roche-Genentech Active, not recruiting
Conditions: Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer Interventions: Drug: crizotinib; Drug: pemetrexed disodium; Other: laboratory biomarker analysis; Other: pharmacological study Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Terminated
Conditions: HER2/Neu Positive; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7 Interventions: Drug: Aromatase Inhibition Therapy; Drug: Carboplatin; Other: Cytology Specimen Collection Procedure; Drug: Docetaxel; Drug: Goserelin Acetate; Other: Laboratory Biomarker Analysis; Biological: Pertuzumab; Other: Quality-of-Life Assessment; Procedure: Therapeutic Conventional Surgery; Biological: Trastuzumab; Radiation: Whole Breast Irradiation Sponsors: National Cancer Institute (NCI); NRG Oncology Active, not recruiting
Conditions: Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer Interventions: Drug: fulvestrant; Drug: anastrozole Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Active, not recruiting
Conditions: Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma Interventions: Biological: Bevacizumab; Biological: Ipilimumab Sponsor: National Cancer Institute (NCI) Active, not recruiting